Propionibacterium acnes resistance:: A worldwide problem
Propionibacterium acnes resistance:: A worldwide problem
复制标题
DOI：
10.1159/000067822
复制
发表时间：
2003-01-01
期刊：
影响因子：
3.4
通讯作者：
Leyden, JJ
中科院分区：
文献类型：
--
作者：
Eady, EA;Gloor, M;Leyden, JJ
针对痤疮丙酸杆菌的抗生素治疗已经成为40多年来的主要治疗方法。尽管多年来广泛使用全身四环素类和红霉素，痤疮丙酸杆菌对抗生素的敏感性变化直到20世纪80年代初才被发现。痤疮丙酸杆菌抗生素敏感性的第一个临床相关变化是在美国引入红霉素和克林霉素局部制剂后不久发现的。到20世纪80年代末，在英国和美国越来越多地发现红霉素MIC水平非常高和四环素MIC升高的痤疮丙酸杆菌菌株。编码核糖体RNA的23S和16S亚基的基因突变首先在英国发现，最近在欧洲、日本、澳大利亚和美国的诊所调查中也发现了这种突变。此外，还发现了无法鉴定这些已知突变的菌株，这表明尚未鉴定的耐药机制已经进化。这些研究结果表明，需要制定战略，以尽量减少使用抗生素治疗痤疮。版权所有（C）2003 S. Karger AG，巴塞尔。
Antibiotic therapy directed against Propionibacterium acnes has been a mainstay of treatment for more than 40 years. Despite years of widespread use of systemic tetracyclines and erythromycin, change in P. acnes sensitivity to antibiotics was not seen until the early 1980s. The first clinically relevant changes in P. acnesantibiotic sensitivity were found in the USA shortly after the introduction of topical formulations of erythromycin and clindamycin. By the late 1980s, P. acnes strains with very high MIC levels for erythromycin and elevated MICs for tetracycline were increasingly found in the UK and the USA. Mutations in the genes encoding the 23S and 16S subunits of ribosomal RNA were first identified in the UK and also seen in a recent survey from clinics in Europe, Japan, Australia and the USA. In addition, strains were found in which these known mutations could not be identified, indicating that as yet unidentified resistance mechanisms have evolved. These findings indicate the need to develop strategies to minimize the use of antibiotics in acne therapy. Copyright (C) 2003 S. Karger AG, Basel.